HROW Harrow, Inc.

30.41USD-5.35%Mkt Cap: 1.14B USDP/E: —

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segment…

Institutional holders20 on file

Key Statistics

Company
Market Cap1.14B USD
Enterprise Value1.43B USD
Revenue (TTM)303.25M USD
Gross Profit204.37M USD
Net Income (TTM)-5.14M USD
Revenue/Share8.12 USD
Last Price30.41 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees373
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)16.26
PEG—
EV/EBITDA90.81
EV/Revenue4.71
P/S3.76
P/B39.09
EPS (TTM)-0.76 USD
EPS (Forward)1.87 USD
52W Range
25.7616% of range54.85
52W High54.85 USD
52W Low25.76 USD
Profitability
Gross Margin75.05%
Oper. Margin-1.99%
EBITDA Margin5.19%
Profit Margin-1.89%
ROE-9.80%
ROA-1.29%
ROIC13.20%
ROCE10.06%
Growth
Revenue Growth38.60%
Earnings Growth810.40%
Cash Flow & Leverage
Operating CF43.86M USD
CapEx (TTM)1.10M USD
FCF Margin-11.28%
FCF Yield-3.00%
Net Debt224.05M USD
Net Debt/EBITDA14.23
Net Debt/FCF—
Balance Sheet
Debt/Equity4.80
Current Ratio2.29
Quick Ratio2.03
Book Value/Sh0.78 USD
Cash/Share2.05 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateFeb 8, 2013
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)62.25 USD
Upside (mean)+104.7%
Target Range42.00 USD – 88.00 USD
42.00+104.7% to mean88.00
# Analysts8
Ownership
Shares Out.37.53M
Float28.28M
Insiders17.99%
Institutions61.71%
Short Interest
Short Ratio12.1d
Short % Float21.03%
Short % Out.18.90%
Shares Short7.09M
Short (prev mo.)7.76M
Technical
SMA 5030.31 (+0.3%)
SMA 20037.30 (-18.5%)
Beta0.17
S&P 52W Chg12.00%
Avg Vol (30d)678.99K
Avg Vol (10d)872.69K
Technical Indicators
RSI (14)52.5
MACD0.2016
MACD Signal-0.2949
MACD Hist.+0.4965
BB Upper32.18 USD
BB Middle29.15 USD
BB Lower26.12 USD
BB Width20.77%
ATR (14)1.822 USD
Vol Ratio (20d)1.27x

About Harrow (NASDAQ: HROW)

›

Harrow (NASDAQ: HROW) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 373 employees.

The shares were at 30.41 USD on 20 November 2026, down 10.4% over 52 weeks. Its 52-week range is 25.76 USD to 54.85 USD: the price is 44.6% below the high and 18.1% above the low.

Its market capitalisation is 1.14B USD.

Harrow reports return on equity of -9.8%, an operating margin of -2.0% and revenue up 38.6% year over year.

Its debt exceeds its cash by 224.05M USD, a debt-to-equity ratio of 4.80. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 62.25 USD is 104.7% above the current price. The next earnings report is expected on 1 March 2027.